Why the study?
Despite its efficacy against several cancers, the use of doxorubicin remains limited due to side effects, especially cardiotoxicity.
Do cardioprotective agents such as nanoparticles, polymers, phytochemicals, and probiotics reduce doxorubicin-induced cardiotoxicity?
Do cardioprotective agents such as nanoparticles, polymers, phytochemicals, and probiotics reduce doxorubicin-induced cardiotoxicity?
This review highlights emerging and classic strategies, such as nanoparticles, phytochemicals, and probiotics, to mitigate doxorubicin-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Requires prospective trials before adoption in cardio-oncology; leaves open comparative efficacy among agents.
Doxorubicin (DOX) is a cytostatic antibiotic from the class of anthracyclines widely used in chemotherapeutic cancer treatments. Despite the efficiency against several types of cancer, the use of DOX remains limited due to the side effects, especially cardiotoxicity. Among the DOX administration strategies, there are the "classic players" such as nanoparticles and polymers, which are capable of DOX delivery directly to interesting neoplastic regions. On the other hand, the "new players" such as phytochemicals and probiotics emerged with the proposal to react with DOX free radicals, reducing the oxidative stress, inflammatory and apoptotic process. Thus, this review aims to report the studies involving these classics and new players along the years that focus on improved administration and reduction of DOX-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Arruda et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: